Invion (IVX) Stock Overview
A clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IVX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Invion Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.084 |
| 52 Week High | AU$0.20 |
| 52 Week Low | AU$0.075 |
| Beta | 0.86 |
| 1 Month Change | -7.69% |
| 3 Month Change | 7.69% |
| 1 Year Change | -30.00% |
| 3 Year Change | -88.00% |
| 5 Year Change | -90.67% |
| Change since IPO | -99.79% |
Recent News & Updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Invion Limited's (ASX:IVX) CEO For Now
Nov 22
We Think Invion (ASX:IVX) Can Afford To Drive Business Growth
Jul 07Here's Why We're Not Too Worried About Invion's (ASX:IVX) Cash Burn Situation
Mar 24Is Invion (ASX:IVX) In A Good Position To Invest In Growth?
Dec 08We're Not Very Worried About Invion's (ASX:IVX) Cash Burn Rate
Aug 16A Look At The Fair Value Of Invion Limited (ASX:IVX)
Nov 04Estimating The Intrinsic Value Of Invion Limited (ASX:IVX)
Mar 23We Think Invion (ASX:IVX) Can Easily Afford To Drive Business Growth
Nov 26
Shareholder Returns
| IVX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 3.7% | 2.8% | 1.9% |
| 1Y | -30.0% | -21.5% | 8.3% |
Return vs Industry: IVX underperformed the Australian Pharmaceuticals industry which returned -21.5% over the past year.
Return vs Market: IVX underperformed the Australian Market which returned 8.3% over the past year.
Price Volatility
| IVX volatility | |
|---|---|
| IVX Average Weekly Movement | 10.7% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: IVX has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: IVX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Thian Chew | www.inviongroup.com |
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer.
Invion Limited Fundamentals Summary
| IVX fundamental statistics | |
|---|---|
| Market cap | AU$7.02m |
| Earnings (TTM) | -AU$8.81m |
| Revenue (TTM) | n/a |
Is IVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVX income statement (TTM) | |
|---|---|
| Revenue | AU$0 |
| Cost of Revenue | AU$1.29m |
| Gross Profit | -AU$1.29m |
| Other Expenses | AU$7.52m |
| Earnings | -AU$8.81m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IVX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/23 09:26 |
| End of Day Share Price | 2026/02/23 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Invion Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.